Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
PART 1:~Inclusion Criteria:~* Willing and able to provide a signed informed consent form prior to participation in any trial-related procedures~* Agrees to adhere to the trial requirements for the length of the trial, including the use of the elamipretide delivery system~* Subject is ≥ 16 and ≤ 80 years of age~* Diagnosed with PMM in the opinion of the investigator and confirmed by an Adjudication Committee~* Woman of childbearing potential must agree to use a highly effective method of birth control~Exclusion Criteria:~* Subject has myopathic signs and or/symptoms due to a neuropathic process or gait problem that would interfere with the 6 minute walk test (6MWT), in the opinion of the Investigator~* Female who are pregnant, planning to become pregnant, or breastfeeding/lactating~* At Screening, the estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.73 m\^2~* Subject has undergone an in-patient hospitalization within the 30 days prior to the Baseline Visit or has a planned hospitalization or a surgical procedure during the trial.~* Subject has clinically significant cardiac disease or prior interventional procedure and/or respiratory disease (medical history or current clinical findings) within 3 months of the Baseline Visit, in the opinion of the Investigator.~* Subject has QTc elongation (using the correction factor utilized at the clinical site) defined as a QTc \>450 msec in male subjects and \>480 msec in female subjects.~* ECG evidence of acute ischemia, atrial fibrillation, or active conduction system abnormalities with the exception of any of the following:~  1. First degree Atrioventricular bock (AV-block)~ 2. Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)~ 3. Right bundle branch block~* Subject has severe vision impairment that, in the opinion of the Investigator, may interfere with their ability to complete all trial requirements~* Subject has a seizure disorder that, in the opinion of the Investigator, may interfere with their ability to complete all trial requirements.~* Active malignancy or any other cancer from which the subject has been disease-free for \< 2 years.~* Subject has a solid organ transplant and/or is currently receiving treatment with therapy for immunosuppression, in the opinion of the Investigator.~* Subject has been previously diagnosed with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection.~* Subject has a history of a systemic eosinophilic illness and/or an eosinophil count \>1,000 cells x10\^6/L at the Screening Visit.~* Subject is currently participating or has participated in an interventional clinical trial (i.e.,investigational product or device, stem cell therapy, gene therapy) within 30 days of the Baseline Visit; or is currently enrolled in a non-interventional clinical trial (except for SPIMM-300) at the Baseline Visit which, in the opinion of the Investigator, may be potentially confounding with results of the current trial (e.g., exercise therapy trial).~* Subject has previously received elamipretide (MTP-131), for any reason.~* Subject has a history of active substance abuse during the year before the Baseline Visit, in the opinion of the Investigator.~* Subject has any prior or current medical condition that, in the judgment of the Investigator, would prevent the subject from safely participating in and/or completing all trial requirements.~PART 2:~Continuation Criteria:~* Subjects must continue to be able and willing to adhere to the trial requirements.~* Subject is appropriate to continue in Part 2 (i.e. subject was compliant in Part 1), in the opinion of the Investigator.~* Subject has not had a serious adverse event (SAE)/serious adverse device effect (SADE) attributed to the elamipretide delivery system.~* Subject has not permanently discontinued the elamipretide delivery system.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: Elamipretide (Type: EXPERIMENTAL): 40 mg (0.5mL) elamipretide subcutaneous (SC) daily
- Part 1: Placebo (Type: PLACEBO_COMPARATOR): Placebo SC daily
- Part 2: Elamipretide open label (Type: EXPERIMENTAL): Elamepretide 40 mg (0.5 mL) SC daily

Based on this trial design, predict the completion outcome and termination type (if applicable).